With the advent of new AR NTD-targeting treatment approaches [33,34,35,36] comes the ability to detect AR-SVs early in the PCa occurrence, and using this approach suggests that these new AR NTD-targeting drugs might be beneficial to a broader spectrum of PCa patients. The gene discussed is AR; the disease is posterior cortical atrophy.